// STATE LEGISLATION TRACKER

Minnesota SF 4365: Omnibus Commerce and Consumer Protection policy bill

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Signed

State: Minnesota
Bill: SF 4365
Session: 2025-2026
Filed: 2026-03-11
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

This is a broad Minnesota commerce and consumer protection package, not a peptide or medical-practice bill. Based on the available title, subjects, and bill text reviewed, it does not directly change compounded peptides, off-label prescribing, telehealth prescribing, naturopathic or NP scope, FDA 503A/503B compounding, controlled substances, or prescription monitoring.

Key Points

No direct peptide prescribing or access change identified
No compounding pharmacy or 503A/503B language identified
No telehealth prescribing restriction or expansion identified
No naturopathic or NP scope change for peptides identified
Drug affordability provisions appear general, not peptide-specific

What to Watch For

Note The Senate file was postponed after HF4188 was substituted, so track the enacted HF4188/Chapter 124 text for final law.

Note General prescription drug affordability changes could matter only if a covered peptide drug is later reviewed.

Note No controlled-substance or prescription monitoring change was identified from the reviewed text.

Where the Bill Stands

SF4365 itself was indefinitely postponed after substitution, but its companion HF4188 became Minnesota Session Law Chapter 124.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws